| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $999,772 ) |
| | 2024 | 2024 | FAKNOSTICS LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42DK141379 | Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis | 000 | 1 | NIH | 9/6/2024 | $325,976 |
| | 2024 | 2024 | FAKNOSTICS LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42HL162392 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | 000 | 2 | NIH | 8/30/2024 | $673,796 |
|
| Issue Date FY: 2023 ( Subtotal = $654,706 ) |
| | 2023 | 2023 | FAKNOSTICS LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42CA240124 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | 000 | 4 | NIH | 8/2/2023 | $654,706 |
|
| Issue Date FY: 2022 ( Subtotal = $970,661 ) |
| | 2022 | 2022 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R41HL162392 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | 001 | 1 | NIH | 8/17/2022 | $0 |
| | 2022 | 2022 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R41HL162392 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis | 000 | 1 | NIH | 8/9/2022 | $299,905 |
| | 2022 | 2022 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42CA240124 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | 002 | 3 | NIH | 7/22/2022 | $670,756 |
| | 2022 | 2021 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42CA240124 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | 000 | 2 | NIH | 2/7/2022 | $0 |
| | 2022 | 2021 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42CA240124 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | 001 | 2 | NIH | 7/21/2022 | $3,556 |
| | 2022 | 2019 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R41CA240124 | Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK) | 000 | 1 | NIH | 7/21/2022 | -$3,556 |
|
| Issue Date FY: 2021 ( Subtotal = $674,537 ) |
| | 2021 | 2021 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42CA240124 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | 001 | 2 | NIH | 8/31/2021 | $19,831 |
| | 2021 | 2021 | FAKNOSTICS, LLC | 475 N 5TH ST | PHOENIX | AZ | 85004-2157 | MARICOPA | USA | R42CA240124 | Development of Non-Catalytic Peptide Inhibitors of Focal Adhesion Kinase (FAK) for Use in Melanoma | 000 | 2 | NIH | 8/12/2021 | $654,706 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2019 | FAKNOSTICS, LLC | 2914 E MINNEZONA AVE | PHOENIX | AZ | 85015-4979 | MARICOPA | USA | R41CA240124 | Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK) | 000 | 1 | NIH | 12/9/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $289,594 ) |
| | 2019 | 2019 | FAKNOSTICS, LLC | 2914 E MINNEZONA AVE | PHOENIX | AZ | 85015-4979 | MARICOPA | USA | R41CA240124 | Discovery of Novel Peptidic Inhibitors of the Non-Catalytic Function of Focal Adhesion Kinase (FAK) | 000 | 1 | NIH | 8/30/2019 | $289,594 |
|
|
